Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Intermediate Capital Group

Investor type Venture Debt
Founders Ken Fox Thomas H. Bartlam


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
The average size of a deal this fund participated in
Portfolio companies 18
Rounds per year 0.61
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 14
Stages of investment
Private Equity

Areas of investment

  • Software
  • Pharmaceutical
  • Health Care
  • Information Technology
  • Biotechnology

In 1989 was created Intermediate Capital Group, which is appeared as VC. The venture was found in Europe in United Kingdom. The main department of described VC is located in the London.

The typical case for the fund is to invest in rounds with 1-2 participants. Despite the Intermediate Capital Group, startups are often financed by HgCapital Trust plc, Ardian. The meaningful sponsors for the fund in investment in the same round are HgCapital Trust plc, Goldman Sachs Asset Management.

Besides, a startup requires to be at the age of more than 20 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Vitaldent, IRIS Software Group For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. We can highlight the next thriving fund investment areas, such as Robotics, Forestry.

Comparing to the other companies, this Intermediate Capital Group performs on 21 percentage points more the average number of lead investments. Deals in the range of more than 100 millions dollars are the general things for fund. The important activity for fund was in 2013. The increased amount of exits for fund were in 2019. Speaking about the real fund results, this VC is 80 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year.

This organization was formed by Ken Fox, Thomas H. Bartlam. The overall number of key employees were 13.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Intermediate Capital Group:
Typical Co-investors
Intermediate Capital Group is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Intermediate Capital Group:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United Kingdom
Funds with similar focus located in United Kingdom:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
East West Bank California, Pasadena, United States
Engie Factory Chile, Region Metropolitana, Santiago
Granicus Group -
Ironbridge Capital Illinois, Oak Brook, United States
leAD Sports & Health Tech Partners Berlin, Berlin, Germany
National Institute of Justice for research -
Nextgen Partners California, Santa Barbara, United States
Qingdao Xiangbai China, Qingdao Shi, Shandong
Quince Associates Colorado, Lakewood, United States
Tsunami Network Partners -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Biomass Energy
Renewable Energy
$118M05 Jan 2022 Marseille, Provence-Alpes-Cote d'Azur, France


$172M15 Jul 2021 St Louis, Missouri, United States

Eliem Therapeutics

Health Care
$60M24 May 2021 Washington, United States


Information Technology
04 May 2021 London, England, United Kingdom

The Execu/Search Group

Staffing Agency
06 Apr 2021 New York, New York, United States

Eliem Therapeutics

Health Care
$80M25 Mar 2021 Washington, United States

Lucid Group Communications

Health Care
10 Mar 2021 England


Information Technology
Professional Services
21 Aug 2020 Oslo, Norway


Human Resources
$127M23 Jun 2020 Framingham, Massachusetts, United States
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.

Led by former Juno and Alder exec, Seattle neurology startup Eliem Therapeutics raises $80M

– Eliem Therapeutics, a new Seattle biotech startup, raised $80m funding.
– The round was led by RA Capital Management and Access Biotechnology, and joined by Intermediate Capital Group.
– The company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures.
– Eliem’s president and CEO is Bob Azelby, who was previously president and CEO of Seattle biotech firm Alder BioPharmaceuticals, which was acquired by Lundbeck for $1.95 billion in 2019.
– He was also chief commercial officer at Seattle-based Juno, which was acquired by Celgene for $9 billion in 2018.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Intermediate Capital Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: